Showing 861 - 880 results of 100,886 for search '(( 5 ((ppm decrease) OR (a decrease)) ) OR ( 5 ((nm decrease) OR (we decrease)) ))', query time: 1.62s Refine Results
  1. 861
  2. 862
  3. 863

    Significant decrease of SMAD4 protein in DBA iPSCs. by Jingping Ge (636557)

    Published 2015
    “…A) Slight decrease of mRNA level of <i>SMAD4</i> in the DBA iPSCs with <i>RPS19</i> or <i>RPL5</i> mutations. …”
  4. 864

    Decrease in oxidative phosphorylation yield in presence of butyrate in perfused liver isolated from fed rats-0 by Jean-Louis Gallis (2926)

    Published 2011
    “…The reference (methylene-diphosphonic acid) is not shown (18.40 ppm) (number of scans = 148). B: 20 min after a perfusion of butyrate 3 mmol/L, effect (from the bottom to the top) of the simultaneous addition of IAA 0.5 mmol/L (2 min) and KCN 2.5 mmol/L (10 min) (number of scans = 60).…”
  5. 865

    Decrease in oxidative phosphorylation yield in presence of butyrate in perfused liver isolated from fed rats-1 by Jean-Louis Gallis (2926)

    Published 2011
    “…The reference (methylene-diphosphonic acid) is not shown (18.40 ppm) (number of scans = 148). B: 20 min after a perfusion of butyrate 3 mmol/L, effect (from the bottom to the top) of the simultaneous addition of IAA 0.5 mmol/L (2 min) and KCN 2.5 mmol/L (10 min) (number of scans = 60).…”
  6. 866
  7. 867
  8. 868

    A phenotype of increased sleepiness in a mouse model of pulmonary hypertension and right ventricular hypertrophy by Eric M. Davis (1733638)

    Published 2018
    “…After PAB, mice spent significantly more time in NREM sleep compared to the control group over a 24 hour period (53.5 ± 1.5% vs. 46.6 ± 1.4%; p < 0.01) and exhibited an inability to both cycle into REM sleep and decrease delta density across the light/sleep period. …”
  9. 869
  10. 870

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  11. 871

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  12. 872

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  13. 873

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  14. 874

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  15. 875
  16. 876

    sC5b-9 patients decrease in patients treated with mycophenolate mofetil. by Joshua M. Thurman (517193)

    Published 2015
    “…When analyzed separately based upon treatment, the decrease in sC5b-9 levels was due to a decrease in patients treated with mycophenolate mofetil (P < 0.001 by linear regression; n = 12 for all time-points). …”
  17. 877
  18. 878
  19. 879

    Synthesis and Structures of a New Series of Silver-Vanadate Hybrid Solids and Their Optical and Photocatalytic Properties by Haisheng Lin (1487347)

    Published 2008
    “…Their optical bandgap sizes were measured to be 2.77 eV for <b>I</b>, 2.95 eV for <b>II</b>, and 2.45 eV for <b>III</b>, which decrease most notably as a result of the band widening for the more extended vanadate structure in <b>III</b>. …”
  20. 880